Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Murray Gordon

Endocrinology, Diabetes & Metabolism Pittsburgh, PA Medical Doctor

NPI 1366414468 CMS profile 152841

420 E North Ave, Suite 205, Pittsburgh, PA 15212

Open in the dashboard

General payments

$60,098

405 records reported · program years 2019–2025

Research payments

$7,651

Paid to them · 20 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$516,039 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Murray Gordon of Pittsburgh, PA is reported in the CMS Open Payments database as having received $60,098 across 405 general payments and $7,651 in research payments paid to them. Separately, studies naming them as principal investigator received $516,039 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $67 3
2024 General $274 13
2023 General $5,272 45
2022 General $14,084 113
2022 Research $1,869 3
2021 General $14,487 94
2021 Research $5,782 17
2020 General $4,763 65
2019 General $21,150 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Murray Gordon
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Murray Gordon were reported at $67. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Murray Gordon Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $21,150 $494 $123–$2,253 $163
2020 $4,763 $335 $85–$1,841 $114
2021 $14,487 $398 $88–$1,981 $132
2022 $14,084 $364 $88–$1,568 $149
2023 $5,272 $420 $113–$1,614 $160
2024 $274 $440 $121–$1,646 $164
2025 $67 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $23,318 138 payments
  2. Novo Nordisk AS $9,868 5 payments
  3. Recordati_Rare_Diseases_Inc. $9,792 23 payments
  4. Corcept Therapeutics $5,365 21 payments
  5. Lilly USA, LLC $3,904 23 payments
  6. HRA Pharma Rare Diseases $2,000 1 payment
  7. Ipsen Biopharmaceuticals, Inc $1,887 8 payments
  8. Amgen Inc. $542 22 payments
  9. Sanofi-Aventis U.S. LLC $304 10 payments
  10. Antares Pharma, Inc. $273 17 payments
  11. Other $2,845 137 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $32,577 16 payments
  2. Travel and Lodging $13,526 21 payments
  3. Food and Beverage $6,450 358 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,755 7 payments
  5. Honoraria $2,750 1 payment
  6. Education $40 2 payments
Products named General payments · program years 2019–2025
  1. Norditropin Growth Hormone $7,303 13 payments
  2. ISTURISA $7,002 20 payments
  3. Norditropin Growth Hormone $6,289 9 payments
  4. Korlym $5,046 18 payments
  5. METOPIRONE $2,000 1 payment
  6. SOMATULINE DEPOT $1,837 7 payments
  7. Ozempic $896 93 payments
  8. RYBELSUS $832 85 payments
  9. Repatha $348 13 payments
  10. Kerendia $235 14 payments
  11. Other $5,165 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Chiasma, Inc. $3,972 5 payments
  2. Corcept Therapeutics $1,700 11 payments
  3. Amryt Pharma Holdings Ltd $1,500 2 payments
  4. Eli Lilly and Company $480 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

54

Median for Internal Medicine: 777

Drug cost

$17,515

Median for Internal Medicine: $73,373

Branded share of claims

68.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 11 $14,835
Synthroid Levothyroxine Sodium Brand 26 $2,282
Levothyroxine Sodium Generic 17 $398

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

425 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record